Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
about
Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitisMechanism of Altered Metformin Distribution in Nonalcoholic SteatohepatitisOrganic and inorganic transporters of the testis: A review.Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Altered Hepatic Transport by Fetal Arsenite Exposure in Diet-Induced Fatty Liver Disease.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Effect of Liver Disease on Hepatic Transporter Expression and Function.Effect of Disease Pathologies on Transporter Expression and Function.Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.
P2860
Q33570726-6FAD81F9-1127-4255-AEAA-1C5853524F6FQ33729768-58DBB702-E6A7-4E45-BFBF-E2F135E981CBQ35156418-0B2AEBF3-B1C8-448D-9A08-0DF43EE3CCD7Q35689076-51F258BC-D005-4DDF-938D-496478C28B1AQ35819589-991B5BE6-0279-4B97-BD54-827C559A477DQ35842935-F63BC66A-D65F-4D6E-BE4B-AA169EE59711Q35973910-484C18B4-CA9E-4C45-9C78-E6F59D89FA55Q36088091-BF0A3F87-1330-407E-AEAF-3B1851D2C32DQ36391044-67A03B92-FF4C-4A69-93A3-80B6532F2839Q37083454-E00A5A0B-A227-4D5E-9660-CE54E49475B8Q38737633-97599B0F-4BC4-427F-8B73-9414E473FA58Q38808182-07B7280C-F83C-4D80-BDA1-A314AA2C383BQ38888360-A65CF27A-3045-4E22-8EAA-1C0B3A7980FFQ39015474-1696B56F-9380-4C21-8053-8552BEF42A6BQ41814330-90D62412-F49A-4C6E-A72F-ED48EBAFC5FCQ47584564-D58FF93E-C716-45E4-9EA7-ABB755163348
P2860
Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Experimental nonalcoholic stea ...... orting polypeptide expression.
@en
Experimental nonalcoholic stea ...... orting polypeptide expression.
@nl
type
label
Experimental nonalcoholic stea ...... orting polypeptide expression.
@en
Experimental nonalcoholic stea ...... orting polypeptide expression.
@nl
prefLabel
Experimental nonalcoholic stea ...... orting polypeptide expression.
@en
Experimental nonalcoholic stea ...... orting polypeptide expression.
@nl
P2093
P2860
P356
P1476
Experimental nonalcoholic stea ...... orting polypeptide expression.
@en
P2093
April D Lake
John D Clarke
Mark J Canet
Nathan J Cherrington
Rhiannon N Hardwick
P2860
P304
P356
10.1124/JPET.113.211284
P407
P577
2014-01-08T00:00:00Z